Stifel Nicolaus Cuts Insulet (NASDAQ:PODD) Price Target to $350.00

Insulet (NASDAQ:PODD) had its price target decreased by Stifel Nicolaus from $370.00 to $350.00 in a research note released on Wednesday, MarketBeat reports. Stifel Nicolaus currently has a buy rating on the medical instruments supplier’s stock.

PODD has been the topic of a number of other reports. Zacks Research downgraded shares of Insulet from a “strong-buy” rating to a “hold” rating in a report on Monday, January 5th. Jefferies Financial Group boosted their target price on shares of Insulet from $375.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Sanford C. Bernstein reduced their target price on shares of Insulet from $410.00 to $380.00 and set an “outperform” rating for the company in a research report on Friday, January 9th. Wolfe Research lifted their price target on shares of Insulet from $350.00 to $375.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. Finally, UBS Group reiterated a “buy” rating on shares of Insulet in a research note on Thursday, December 18th. Twenty research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $374.10.

Insulet Trading Down 0.5%

NASDAQ:PODD opened at $241.93 on Wednesday. Insulet has a 52 week low of $230.05 and a 52 week high of $354.88. The firm has a 50-day moving average price of $283.49 and a two-hundred day moving average price of $307.72. The company has a debt-to-equity ratio of 0.68, a quick ratio of 2.18 and a current ratio of 2.87. The firm has a market cap of $17.02 billion, a price-to-earnings ratio of 70.12, a price-to-earnings-growth ratio of 1.37 and a beta of 1.41.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share for the quarter, topping analysts’ consensus estimates of $1.13 by $0.11. The firm had revenue of $521.70 million for the quarter, compared to the consensus estimate of $678.70 million. Insulet had a return on equity of 24.36% and a net margin of 9.76%.The company’s revenue was up 29.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.08 EPS. On average, equities analysts expect that Insulet will post 3.92 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Insulet

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Global Retirement Partners LLC raised its holdings in shares of Insulet by 57.0% in the 4th quarter. Global Retirement Partners LLC now owns 391 shares of the medical instruments supplier’s stock valued at $111,000 after acquiring an additional 142 shares in the last quarter. Mach 1 Financial Group LLC purchased a new stake in Insulet in the fourth quarter valued at approximately $898,000. Leonteq Securities AG bought a new stake in Insulet during the fourth quarter valued at approximately $57,000. ABN Amro Investment Solutions lifted its holdings in shares of Insulet by 242.1% during the 4th quarter. ABN Amro Investment Solutions now owns 2,928 shares of the medical instruments supplier’s stock worth $832,000 after acquiring an additional 2,072 shares during the last quarter. Finally, IFP Advisors Inc grew its position in Insulet by 12.5% in the fourth quarter. IFP Advisors Inc now owns 1,576 shares of the medical instruments supplier’s stock worth $448,000 after acquiring an additional 175 shares in the last quarter.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.